Nonin Medical Announces United Kingdom and Ireland Distribution Agreement with Terumo Cardiovascular Group in Europe for Nonin's SenSmart™ Universal Oximetry System
Nonin Medical, a leader in noninvasive medical monitoring, today announced that it has entered into a multi-year distribution agreement with Terumo Cardiovascular Group in Europe. As of January 2014, Terumo Cardiovascular Group will distribute Nonin's SenSmart™ Universal Oximetry System to all hospitals in the UK and Ireland. A similar distribution agreement between the two companies for the United States was announced in April 2013. Terumo manufactures and markets medical devices for the global cardiac surgery market.
The Nonin SenSmart Universal Oximetry System is the first dedicated oximeter system that provides measurements of both regional oximetry (rSO2) and pulse oximetry (SpO2). While providing industry-leading rSO2 accuracy,* the SenSmart system provides comprehensive monitoring of up to six-channels of rSO2 and SpO2 monitoring. No other oximeter system provides more than four channels of monitoring. The signal processor is substantially smaller than previous versions, making the SenSmart system ideal for use in a variety of settings where space is an issue, such as neonatal incubators. The system allows anesthesiologists, perfusionists, cardiovascular surgeons, neonatologists, intensivists, and other clinicians to quickly react to reverse tissue ischemia events before they become critical.
"Nonin Medical is pleased that this agreement, which takes advantage of Terumo's extensive cardiovascular relationships in heart hospitals in the UK and Ireland, will accelerate the adoption of the SenSmart System in the UK and Ireland," said Chris Holland, Vice President of Business Development for Nonin Medical. "Nonin's SpO2 and rSO2technologies are cost-effective monitoring tools that help aid clinicians in caring for their patients with early detection of potentially dangerous events."
"Terumo UK is extremely excited about this collaboration with Nonin Medical and the opportunity it provides to both our current and new customers by adding their state-of-the-art regional oximetry to our current range of inline patient monitoring technologies," said Terumo UK Branch Manager Graham Walker. "We believe that this new addition to our product portfolio will be seen as a further indication of our commitment to provide the latest technology available to the UK cardiovascular market."
Cardiovascular surgery is a common procedure in the UK and Ireland. Regional oximetry-monitored procedures typically allow for early indication of oxygen desaturation that could lead to stroke, neurocognitive decline and other neurological or major organ injuries resulting from inadequate oxygen saturation. Regional oximetry solutions have been shown to reduce the cost of post-operative care and improve patient outcomes.1
Advantages of the SenSmart Universal Oximetry System include:
- Versatile: The SenSmart system provides clinicians the ability to use Nonin SenSmart-compatible rSO2 sensors and/or SpO2 sensors to monitor up to six sites on neonatal, pediatric and adult patients.
- Highly Accurate: The SenSmart System's EQUANOX™ Advance rSO2 Sensor provides clinicians with state-of-the-art accuracy. Nonin's reusable SpO2 Soft Sensors provide fast, accurate and reliable readings even in patients with low perfusion or in the presence of motion.
- Easy to Use: The smaller, lighter and less-intrusive SenSmart Universal Signal Processors automatically recognize and display either the rSO2 or SpO2 signal, as well as the colored channel number you have chosen to connect to.
- Convenient: The portable, easy-to-operate SenSmart Monitor offers Bluetooth® wireless connectivity and comes with SenSmart Download Software.
- Pediatric-Specific Spacing of Light Emitters and Detectors: Designed specifically for patients weighing less than 40 kg with varying levels of myelination.
For more information about the Nonin SenSmart System, visit www.sensmart.com.
* Accuracy data based on 8004CA sensor clinical results.
1. Goldman SM, Sutter FP, Wertan MA, et al. Outcome improvement and cost reduction in an increasingly morbid cardiac surgery population. Semin Cardiothorac Vasc Anesth 2006;10:171-5.
©2014 Terumo Cardiovascular Systems Corporation. Terumo® is a trademark of Terumo Corporation. SenSmart™ and EQUANOX™ are trademarks of Nonin Medical, Inc. Bluetooth® is a trademark of Bluetooth SIG.
Nonin Medical, Inc. invented the finger pulse oximeter (the original Onyx® brand) and designs and manufactures noninvasive medical monitoring solutions that meet customers’ technology needs today and tomorrow. Headquartered in Plymouth, Minn., USA, with an additional customer service center in Amsterdam, the Netherlands, Nonin Medical sells its pulse and regional oximeters, capnographs, sensors and software to health professionals and consumers in more than 125 countries. The company has more than 300 OEM partners worldwide. For more information, visit nonin.com.
About Terumo Europe Cardiovascular Systems
Terumo Europe Cardiovascular Systems is an integral part of the Terumo's family of cardiovascular businesses and is committed to developing innovative technologies for the treatment of cardiovascular disease. In Europe, Terumo Cardiovascular Systems provides products and service such as Capiox® Oxygenators, customized Tubing Sets, CDI®Blood Parameter Monitoring System, Pall® filter brand products, VirtuoSaph Plus®, the Endoscopic Vein Harvesting System. For more information, visit www.terumo-europe.com.
About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.